| pubmed-article:578932 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:578932 | lifeskim:mentions | umls-concept:C0341628 | lld:lifeskim |
| pubmed-article:578932 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:578932 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:578932 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:578932 | lifeskim:mentions | umls-concept:C0680536 | lld:lifeskim |
| pubmed-article:578932 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:578932 | pubmed:dateCreated | 1977-12-29 | lld:pubmed |
| pubmed-article:578932 | pubmed:abstractText | Diurnal variation of blood sugar, C-peptide immunoreactivity (CPR), free insulin and total insulin were measured in 10 insulin requiring diabetics after obtaining adequate control of diabetes with commercial lente insulin treatment. Following these tests, insulin treatment were changed to monocomponent insulin (MC-insulin) from commercial lente insulin treatment in all subjects and the same tests were performed at 7th day of MC-insulin treatment. Diurnal variations of blood sugar in both groups were not changed significantly. Also changes in CPR of both groups were nearly same magnitude and endogenous insulin secretion in these insulin treated diabetics were suggested except a case of juvenile diabetic subject. However personal variation were great in diabetics with high antibody titer, diurnal variations of total extractable insulin in both groups were quite comparable. And mean diurnal changes in free insulin were resemble to that of CPR. All of these data suggested that clinical effects of MC-insulin and commercial insulin treatment on insulin requiring diabetics were comparable except insulin antibody or proinsulinspecific antibody production. | lld:pubmed |
| pubmed-article:578932 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:578932 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:578932 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:578932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:578932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:578932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:578932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:578932 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:578932 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:578932 | pubmed:issn | 0033-8303 | lld:pubmed |
| pubmed-article:578932 | pubmed:author | pubmed-author:NakashimaYY | lld:pubmed |
| pubmed-article:578932 | pubmed:author | pubmed-author:MatsumuraSS | lld:pubmed |
| pubmed-article:578932 | pubmed:author | pubmed-author:NishidaSS | lld:pubmed |
| pubmed-article:578932 | pubmed:author | pubmed-author:OyamaHH | lld:pubmed |
| pubmed-article:578932 | pubmed:author | pubmed-author:TenkuAA | lld:pubmed |
| pubmed-article:578932 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:578932 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:578932 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:578932 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:578932 | pubmed:pagination | 158-62 | lld:pubmed |
| pubmed-article:578932 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-H... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-B... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-D... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-A... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-I... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-I... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-F... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-M... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-A... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-C... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-M... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-D... | lld:pubmed |
| pubmed-article:578932 | pubmed:meshHeading | pubmed-meshheading:578932-C... | lld:pubmed |
| pubmed-article:578932 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:578932 | pubmed:articleTitle | [Clinical effects of monocomponent insulin and commercial insulin preparations on insulin requiring diabetics (author's transl)]. | lld:pubmed |
| pubmed-article:578932 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:578932 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:578932 | pubmed:publicationType | English Abstract | lld:pubmed |
